Therefore, KIR2DS4f gene-positive patients might have a potential to produce CD4+CD28-KIR2DS4+ T cells contributing to more severe forms of RA, which would be more resistant to therapy, including MTX treatment. This evidence concerns the gene CD28 and rheumatoid arthritis.